MovDisordV3, PascalFrancis, Curation, bibRecord, 002976

Treatment of Dysarthria Following Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease

Identifieur interne : 002976 ( PascalFrancis/Curation ); précédent : 002975; suivant : 002977

Treatment of Dysarthria Following Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease

Auteurs : Elina Tripoliti [Royaume-Uni] ; Laura Strong [Royaume-Uni] ; Freya Hickey [Royaume-Uni] ; Tom Foltynie [Royaume-Uni] ; Ludvic Zrinzo [Royaume-Uni] ; Joseph Candelario [Royaume-Uni] ; Marwan Hariz [Royaume-Uni] ; Patricia Limousin [Royaume-Uni]

Source :

Movement disorders [ 0885-3185 ] ; 2011.

RBID : Pascal:12-0026981

Descripteurs français

Pascal (Inist)
- Dysarthrie, Maladie de Parkinson, Pathologie du système nerveux, Traitement, Noyau sousthalamique, Parole, Stimulation cérébrale profonde.

English descriptors

KwdEn :
- Deep brain stimulation, Dysarthria, Nervous system diseases, Parkinson disease, Speech, Subthalamic nucleus, Treatment.

Abstract

Background: Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN-DBS. Methods: The LSVT was administered to 10 patients with STN-DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures. Results: Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating. Conclusions: Treatment of dysarthria following STN-DBS needs further investigation because of the variable response to LSVT.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 26`
A06				`@2 13`
A08	`01`	`1`	`ENG`	`@1 Treatment of Dysarthria Following Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease`
A11	`01`	`1`		`@1 TRIPOLITI (Elina)`
A11	`02`	`1`		`@1 STRONG (Laura)`
A11	`03`	`1`		`@1 HICKEY (Freya)`
A11	`04`	`1`		`@1 FOLTYNIE (Tom)`
A11	`05`	`1`		`@1 ZRINZO (Ludvic)`
A11	`06`	`1`		`@1 CANDELARIO (Joseph)`
A11	`07`	`1`		`@1 HARIZ (Marwan)`
A11	`08`	`1`		`@1 LIMOUSIN (Patricia)`
A14	`01`			`@1 UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square @2 London @3 GBR @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A20				`@1 2434-2437`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000505925010220`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 24 ref.`
A47	`01`	`1`		`@0 12-0026981`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN-DBS. Methods: The LSVT was administered to 10 patients with STN-DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures. Results: Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating. Conclusions: Treatment of dysarthria following STN-DBS needs further investigation because of the variable response to LSVT.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Dysarthrie @5 01`
C03	`01`	`X`	`ENG`	`@0 Dysarthria @5 01`
C03	`01`	`X`	`SPA`	`@0 Disartria @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Traitement @5 09`
C03	`04`	`X`	`ENG`	`@0 Treatment @5 09`
C03	`04`	`X`	`SPA`	`@0 Tratamiento @5 09`
C03	`05`	`X`	`FRE`	`@0 Noyau sousthalamique @5 10`
C03	`05`	`X`	`ENG`	`@0 Subthalamic nucleus @5 10`
C03	`05`	`X`	`SPA`	`@0 Núcleo subtalámico @5 10`
C03	`06`	`X`	`FRE`	`@0 Parole @5 11`
C03	`06`	`X`	`ENG`	`@0 Speech @5 11`
C03	`06`	`X`	`SPA`	`@0 Habla @5 11`
C03	`07`	`X`	`FRE`	`@0 Stimulation cérébrale profonde @4 CD @5 96`
C03	`07`	`X`	`ENG`	`@0 Deep brain stimulation @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Trouble de la communication @5 38`
C07	`01`	`X`	`ENG`	`@0 Communication disorder @5 38`
C07	`01`	`X`	`SPA`	`@0 Trastorno comunicación @5 38`
C07	`02`	`X`	`FRE`	`@0 Trouble du langage @5 39`
C07	`02`	`X`	`ENG`	`@0 Language disorder @5 39`
C07	`02`	`X`	`SPA`	`@0 Trastorno lenguaje @5 39`
C07	`03`	`X`	`FRE`	`@0 Trouble neurologique @5 40`
C07	`03`	`X`	`ENG`	`@0 Neurological disorder @5 40`
C07	`03`	`X`	`SPA`	`@0 Trastorno neurológico @5 40`
C07	`04`	`X`	`FRE`	`@0 Encéphale @5 41`
C07	`04`	`X`	`ENG`	`@0 Encephalon @5 41`
C07	`04`	`X`	`SPA`	`@0 Encéfalo @5 41`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central @5 42`
C07	`05`	`X`	`ENG`	`@0 Central nervous system @5 42`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso central @5 42`
C07	`06`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 43`
C07	`06`	`X`	`ENG`	`@0 Cerebral disorder @5 43`
C07	`06`	`X`	`SPA`	`@0 Encéfalo patología @5 43`
C07	`07`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 44`
C07	`07`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 44`
C07	`07`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 44`
C07	`08`	`X`	`FRE`	`@0 Maladie dégénérative @5 45`
C07	`08`	`X`	`ENG`	`@0 Degenerative disease @5 45`
C07	`08`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 45`
C07	`09`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 46`
C07	`09`	`X`	`ENG`	`@0 Central nervous system disease @5 46`
C07	`09`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 46`
N21				`@1 009`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000338

Links to Exploration step

Pascal:12-0026981

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment of Dysarthria Following Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease</title>
<author><name sortKey="Tripoliti, Elina" sort="Tripoliti, Elina" uniqKey="Tripoliti E" first="Elina" last="Tripoliti">Elina Tripoliti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Strong, Laura" sort="Strong, Laura" uniqKey="Strong L" first="Laura" last="Strong">Laura Strong</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Hickey, Freya" sort="Hickey, Freya" uniqKey="Hickey F" first="Freya" last="Hickey">Freya Hickey</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Foltynie, Tom" sort="Foltynie, Tom" uniqKey="Foltynie T" first="Tom" last="Foltynie">Tom Foltynie</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Zrinzo, Ludvic" sort="Zrinzo, Ludvic" uniqKey="Zrinzo L" first="Ludvic" last="Zrinzo">Ludvic Zrinzo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Candelario, Joseph" sort="Candelario, Joseph" uniqKey="Candelario J" first="Joseph" last="Candelario">Joseph Candelario</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Hariz, Marwan" sort="Hariz, Marwan" uniqKey="Hariz M" first="Marwan" last="Hariz">Marwan Hariz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Limousin, Patricia" sort="Limousin, Patricia" uniqKey="Limousin P" first="Patricia" last="Limousin">Patricia Limousin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0026981</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 12-0026981 INIST</idno>
<idno type="RBID">Pascal:12-0026981</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000338</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002976</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment of Dysarthria Following Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease</title>
<author><name sortKey="Tripoliti, Elina" sort="Tripoliti, Elina" uniqKey="Tripoliti E" first="Elina" last="Tripoliti">Elina Tripoliti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Strong, Laura" sort="Strong, Laura" uniqKey="Strong L" first="Laura" last="Strong">Laura Strong</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Hickey, Freya" sort="Hickey, Freya" uniqKey="Hickey F" first="Freya" last="Hickey">Freya Hickey</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Foltynie, Tom" sort="Foltynie, Tom" uniqKey="Foltynie T" first="Tom" last="Foltynie">Tom Foltynie</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Zrinzo, Ludvic" sort="Zrinzo, Ludvic" uniqKey="Zrinzo L" first="Ludvic" last="Zrinzo">Ludvic Zrinzo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Candelario, Joseph" sort="Candelario, Joseph" uniqKey="Candelario J" first="Joseph" last="Candelario">Joseph Candelario</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Hariz, Marwan" sort="Hariz, Marwan" uniqKey="Hariz M" first="Marwan" last="Hariz">Marwan Hariz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Limousin, Patricia" sort="Limousin, Patricia" uniqKey="Limousin P" first="Patricia" last="Limousin">Patricia Limousin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Deep brain stimulation</term>
<term>Dysarthria</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Speech</term>
<term>Subthalamic nucleus</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dysarthrie</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Traitement</term>
<term>Noyau sousthalamique</term>
<term>Parole</term>
<term>Stimulation cérébrale profonde</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN-DBS. Methods: The LSVT was administered to 10 patients with STN-DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures. Results: Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating. Conclusions: Treatment of dysarthria following STN-DBS needs further investigation because of the variable response to LSVT.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>13</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Treatment of Dysarthria Following Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TRIPOLITI (Elina)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>STRONG (Laura)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HICKEY (Freya)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>FOLTYNIE (Tom)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ZRINZO (Ludvic)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CANDELARIO (Joseph)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HARIZ (Marwan)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>LIMOUSIN (Patricia)</s1>
</fA11>
<fA14 i1="01"><s1>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>2434-2437</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000505925010220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0026981</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN-DBS. Methods: The LSVT was administered to 10 patients with STN-DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures. Results: Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating. Conclusions: Treatment of dysarthria following STN-DBS needs further investigation because of the variable response to LSVT.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dysarthrie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dysarthria</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Disartria</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Noyau sousthalamique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Subthalamic nucleus</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Núcleo subtalámico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Parole</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Speech</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Habla</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Stimulation cérébrale profonde</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Deep brain stimulation</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Trouble de la communication</s0>
<s5>38</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Communication disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Trastorno comunicación</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Trouble du langage</s0>
<s5>39</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Language disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Trastorno lenguaje</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Encephalon</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>46</s5>
</fC07>
<fN21><s1>009</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002976 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002976 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0026981
   |texte=   Treatment of Dysarthria Following Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Treatment of Dysarthria Following Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease

Treatment of Dysarthria Following Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri